Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris NV has increased its global peak sales estimate for deucrictibant to $1.65 billion by 2037, reflecting stronger market expectations for this novel treatment targeting hereditary angioedema (HAE). The clinical data showcased a 100% achievement of "well-controlled HAE" status among participants at the final time points, indicating profound and durable quality of life benefits from the treatment. Additionally, given the estimated prevalence of HAE and the lack of approved therapies, deucrictibant is strategically positioned to capture significant market share if it receives approval, bolstered by consistent efficacy data across multiple studies.

Pharvaris NV faces significant risks in its development trajectory due to insufficient de-risking of bradykinin B2 receptor antagonism specifically in chronic prophylaxis, which raises concerns about the efficacy and market acceptance of its lead candidate, deucrictibant. The highly competitive environment within the Hereditary Angioedema (HAE) market, dominated by established therapies and segment leaders, poses additional challenges for Pharvaris in gaining traction and market share. Furthermore, the anticipated approvals of multiple subcutaneous therapies within the next 36 months could further dilute Pharvaris's positioning, potentially undermining the uptake of deucrictibant.